News | September 24, 2008

Lantheus to Use Competitive Pricing Against Generic Cardiac Agents

September 23, 2008 – In response to the FDA approval of Covidien’s ANDA for generic Kit for the Preparation of Technetium Tc99m Sestamibi Injection, Lantheus Medical Imaging said it will compete with competitive pricing.

Lantheus Medical Imaging stated that it acknowledges the FDA approval of Covidien’s ANDA for generic Kit for the Preparation of Technetium Tc99m Sestamibi Injection, and that it will continue to market Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), a myocardial perfusion imaging agent, in the upcoming competitive generic marketplace with competitive pricing.

In Lantheus’ response, the company also stated that “it is not authorizing a generic version of Cardiolite,” and emphasized the history of the agent, pointing out that “Cardiolite is the only technetium-labeled myocardial perfusion agent that has been used to image more than 40 million patients, the subject of more than 10,000 publications and the imaging agent of choice within a number of seminal clinical trials, including DIAD, COURAGE, BARI-2D, ERASE, INSPIRE, IMAGING HF, STITCH and CHRISTMAS.”

For more information: www.lantheus.com and http://www.cardiolite.com/hcp/pi/pi.htm

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...